Press release Communiqué de presse

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter

Press release Communiqué de presse


December 1, 2006 1 December, 2006

Breakthrough Magnetic Resonance Imaging Technique Developed for Diabetes's Cellular Therapy: Published in November Issue of Medical Journal, "Diabetes"


Kelowna, B.C. -- Sernova Corp. ("Sernova") is pleased to announce the November issue of the medical journal, Diabetes, has published a breakthrough MRI method for monitoring the viability of transplanted pancreas islets. The technique was developed by the research group led by Dr. David White, Chair of Sernova's Scientific Advisory Board, in collaboration with Dr. Paula Foster and the imaging group at the Robarts Research Institute in London, Ontario.

The breakthrough imaging method will empower physicians and researchers to monitor the survival of transplanted, insulin-producing islet clusters in patients treated with the "Edmonton Protocol." Sernova will use the technique to verify the longevity of islets in its cellular therapy approach of transplanting both Sertoli and islet cells.

"This is an important development for Sernova because real time tracking of islets gives immediate feedback to our research team on the success of transplant experiments," said Sernova President Justin Leushner. "It will also provide valuable data for the FDA and other health regulators on the long-term efficacy of cellular therapy for diabetes."

About Sernova Sernova Corp. is a Canadian based, health sciences company focused on commercializing medical technologies and currently working to cure insulin dependent diabetes. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. Over $100 billion per year is spent in the US on treating diabetes and its complications.

This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

ON BEHALF OF THE BOARD

"Justin Leushner"

Justin Leushner, President

For further information contact: TEL: (888) 318-7062 FAX: (250) 868-8493 info@sernovacorp.com www.sernovacorp.com

Phil Morehouse Executive Vice President Sernova Corp.

THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.